GCP
ZBIO

GSA Capital Partners’s Zenas BioPharma ZBIO Stock Holding History

GSA Capital Partners’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,956
Closed -$325K – 2240
2025
Q4 		$325K Buy
+8,956
New +$295K 0.03% 1124
2025
Q2 		– Sell
-31,757
Closed -$251K – 2226
2025
Q1 		$251K Sell
31,757
-24,282
-43% -$190K 0.02% 1269
2024
Q4 		$459K Buy
+56,039
New +$874K 0.03% 962

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

GSA Capital Partners's ZBIO Position: Q1 2026 in Review

GSA Capital Partners sold out of Zenas BioPharma (ZBIO) in Q1 2026, closing a stake of 8,956 shares — an estimated $325K sold.

GSA Capital Partners first reported a position in ZBIO in Q4 2024 and held it in 3 quarters. The position peaked at $459K in Q4 2024. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • GSA Capital Partners reported no remaining Zenas BioPharma position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 8,956 Zenas BioPharma shares in Q1 2026, an estimated $325K.
  • GSA Capital Partners first reported a position in Zenas BioPharma in Q4 2024 and held it in 3 quarters.
  • GSA Capital Partners's Zenas BioPharma position peaked at $459K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.